Search

everythinglearnresearchcommunity

for

Search:↓

The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.

Both cyproterone acetate and spironolactone effectively reduce hair growth in women with hirsutism.

The patient's long-term hair loss was caused by leukemia treatments and low estrogen levels, worsened by her genetic tendency for hair loss.

Finasteride and CPA-EE2 equally reduce hirsutism, but affect hormone levels differently.

Cyproterone acetate-estrogen most effective for hirsutism, but consider side effects and patient needs.

The paper suggests that a decrease in estrogen receptor activity may cause sexual dysfunction syndromes and proposes hormonal treatments.

Androgen excess disorders in women were effectively treated with spironolactone, estrogen, and dexamethasone.

Cyproterone acetate is the preferred treatment for women's hyperandrogenism when estrogen/progestogen use is safe.

Estrogen affects how vitamin A is processed in mouse skin, which may impact acne treatment, hair growth, and skin defense.

Cyproterone acetate treatment is safe and causes mild feminization, which increases with added estrogen.

Young women in West Bengal, India, with PCOS often have estrogen resistance, leptin receptor issues, folate deficiency, T2DM, and acanthosis, commonly linked to obesity.

A postmenopausal woman's facial redness, acne, and excess hair were caused by too much hormone therapy for insomnia, but improved after stopping the treatment.

Higher GPER-1 levels are linked to more severe and shorter-duration androgenetic alopecia, suggesting GPER-1 as a potential treatment target.

Birth control pills are effective for treating women with too much male hormone.

Spironolactone is effective and safe for treating acne with minimal side effects.

Finasteride treatment changes urine metabolomics and steroid signatures, potentially monitoring effectiveness but may cause sexual side effects.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

New treatments for male hypogonadism are effective and should be personalized.

For women with moderate to severe unwanted hair growth or acne, birth control pills are the first choice, with other medications like cyproterone, spironolactone, flutamide, or finasteride as alternatives, and permanent hair removal should be done with electrolysis or laser.

The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

Finasteride causes harmful organ changes in female mice.

Transgender women can develop feminine traits and improve their quality of life through hormone therapy and surgery, but results vary and access to surgery can be limited.

Spironolactone can reduce hair growth and testosterone in hirsutism, but is less effective than combined treatments.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Oral contraceptives help treat hyperandrogenic disorders, improving symptoms like excessive hair and acne.

The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.

PCOS is linked to a higher risk of endometrial cancer but not ovarian or breast cancer, and more research is needed on its role in cancer development and treatment effects.

The conclusion is to diagnose PCOS with just hyperandrogenism and irregular periods, and treat with lifestyle changes and basic medications.